GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Float Percentage Of Total Shares Outstanding

Neurocrine Biosciences (FRA:NB3) Float Percentage Of Total Shares Outstanding : 85.39% (As of May. 25, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neurocrine Biosciences's float shares is 85.94 Mil. Neurocrine Biosciences's total shares outstanding is 100.64 Mil. Neurocrine Biosciences's float percentage of total shares outstanding is 85.39%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neurocrine Biosciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neurocrine Biosciences's Institutional Ownership is 60.53%.


Neurocrine Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Neurocrine Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=85.94/100.64
=85.39%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurocrine Biosciences (FRA:NB3) Business Description

Industry
Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (FRA:NB3) Headlines

No Headlines